IMMUTEP Ltd (IMMP) stock
IMMPNasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as PRRUF
$3.25−0.01 (-0.31%)
Close on Nov 18, 2026Market cap $23.95MP/E –Yield –
Immutep net income
Net income is the profit left for shareholders after every expense, interest and tax.
For fiscal 2026 it was -A$79.30M. The highest annual figure on record is -A$9.37M in fiscal 2017.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | -A$79.30M | – |
| FY2025 | Jun 30, 2025 | -A$61.43M | – |
| FY2024 | Jun 30, 2024 | -A$42.72M | – |
| FY2023 | Jun 30, 2023 | -A$39.90M | – |
| FY2022 | Jun 30, 2022 | -A$32.21M | – |
| FY2021 | Jun 30, 2021 | -A$29.90M | – |
| FY2020 | Jun 30, 2020 | -A$13.47M | – |
| FY2019 | Jun 30, 2019 | -A$18.34M | – |
| FY2018 | Jun 30, 2018 | -A$12.75M | – |
| FY2017 | Jun 30, 2017 | -A$9.37M | – |
| FY2016 | Jun 30, 2016 | -A$62.02M | – |
See a number that looks wrong?